Wells Fargo & Company Forecasts Strong Price Appreciation for Cencora (NYSE:COR) Stock

Cencora (NYSE:COR – Get Free Report) had its price target boosted by equities research analysts at Wells Fargo & Company from $395.00 to $400.00 in a report issued on Tuesday, MarketBeat.com reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 14.74% from the company’s current price.

COR has been the topic of a number of other research reports. Morgan Stanley boosted their price target on Cencora from $346.00 to $377.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Evercore reiterated an “outperform” rating and issued a $350.00 price objective (up from $330.00) on shares of Cencora in a report on Thursday, August 6th. Bank of America increased their price objective on Cencora from $285.00 to $310.00 in a report on Tuesday, July 21st. Robert W. Baird lifted their price objective on Cencora from $373.00 to $375.00 and gave the stock an “outperform” rating in a research report on Thursday, October 22nd. Finally, JPMorgan Chase & Co. boosted their target price on Cencora from $390.00 to $413.00 and gave the company an “overweight” rating in a research note on Tuesday, November 10th. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $381.00.

View Our Latest Report on COR

Cencora Price Performance

Shares of Cencora stock opened at $348.60 on Tuesday. The firm has a market cap of $66.52 billion, a PE ratio of 19.51, a price-to-earnings-growth ratio of 1.81 and a beta of 0.58. Cencora has a 12-month low of $244.82 and a 12-month high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.94 and a debt-to-equity ratio of 3.01. The company’s fifty day simple moving average is $328.67 and its two-hundred day simple moving average is $317.17.

Cencora (NYSE:COR – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.58 by $0.08. The firm had revenue of $88.35 billion for the quarter, compared to analysts’ expectations of $87.95 billion. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.84 earnings per share. As a group, equities analysts expect that Cencora will post 19.58 EPS for the current year.

Insider Buying and Selling at Cencora

In related news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. The trade was a 36.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.38% of the company’s stock.

Hedge Funds Weigh In On Cencora

Institutional investors have recently bought and sold shares of the stock. Innovator Capital Management LLC bought a new stake in Cencora during the 3rd quarter valued at approximately $3,183,000. Zacks Investment Management grew its holdings in shares of Cencora by 2.5% during the 3rd quarter. Zacks Investment Management now owns 47,754 shares of the company’s stock worth $14,338,000 after acquiring an additional 1,150 shares during the period. iSAM Funds UK Ltd purchased a new position in shares of Cencora during the 3rd quarter worth approximately $348,000. Integrated Wealth Concepts LLC grew its holdings in shares of Cencora by 49.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 8,668 shares of the company’s stock worth $2,603,000 after acquiring an additional 2,877 shares during the period. Finally, Bruce G. Allen Investments LLC raised its position in shares of Cencora by 1,866.7% in the 3rd quarter. Bruce G. Allen Investments LLC now owns 590 shares of the company’s stock worth $177,000 after acquiring an additional 560 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Company Profile

(Get Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Recommended Stories

Analyst Recommendations for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.